In a development within the pharmaceutical and tax sectors, Senate Finance Committee Chair Ron Wyden, D-Ore., has escalated his focus on Pfizer, a leading global pharmaceutical company. This heightened scrutiny forms part of a broader, three-year investigation into the tax strategies of major U.S. drugmakers, specifically examining how recent tax legislation has influenced corporate tax liabilities.
Overview of the Investigation
Senator Wyden’s inquiry aims to clarify the extent to which Pfizer, among other pharmaceutical giants, has leveraged changes introduced by the 2017 Tax Cuts and Jobs Act to minimize its tax obligations. Wyden’s latest actions involve probing Pfizer’s international tax practices, particularly given the company’s significantly lower effective tax rates compared to the U.S. corporate tax rate of 21%. In 2022, Pfizer reported an effective tax rate of 9.6%, and in 2023, the company disclosed a negative tax rate, indicating that its tax refunds exceeded its payments for the year. This comes in the context of Pfizer’s revenue, exceeding $364 billion between 2018 and 2023.
Impact of the 2017 Tax Cuts and Jobs Act
The crux of Wyden’s investigation revolves around the 2017 Tax Cuts and Jobs Act, which reduced the corporate tax rate from 35% to 21% and introduced the Global Intangible Low-Taxed Income (GILTI) provision. GILTI targets U.S. companies that own more than 50% of foreign corporations and generate income from intangible assets, such as copyrights, patents, and other intellectual property in low-tax jurisdictions. It employs a formulaic approach to tax this income at an effective rate ranging from 10.5% to 13%. Wyden’s analysis suggests that this provision has been a significant factor in Pfizer’s reduced tax rate, which dropped by 75% following the law’s enactment.
Wyden’s recent correspondence with Pfizer CEO Dr. Albert Bourla seeks detailed information on the company’s tax and earnings practices. While Pfizer generated 42% of its global sales from the U.S. in 2022, only 16% of its profits were reported in the U.S. This disparity raised concerns about the use of profit-shifting techniques to lower tax liabilities.
Offshore Subsidiaries and Tax Incentives
A key focus of the investigation is Pfizer’s utilization of offshore subsidiaries and the tax incentives these entities benefit from. Pfizer has secured tax incentives in Puerto Rico and Singapore, with agreements extending to 2053 and 2048, respectively. Wyden is also examining whether Pfizer has similar tax arrangements with Ireland.
The difference between where Pfizer earns its revenue and where it reports its profits is key. For instance, in 2022, Pfizer reported a $4.4 billion loss in the U.S. on $27 billion in U.S. sales, while showing $5.4 billion in profits from $31 billion in foreign sales earnings.
Broader Implications
This investigation is part of a broader effort by Wyden to scrutinize the tax practices of the pharmaceutical industry, which he contends may have exploited the 2017 tax law to reduce tax liabilities on U.S. prescription drug sales. Wyden’s committee has previously reviewed other pharmaceutical companies such as AbbVie, Amgen, Bristol Myers Squibb, and Merck. Findings from these inquiries revealed a decline in the average effective tax rate of U.S. pharmaceutical companies, dropping from 19.6% in 2014-2016 to 11.6% in 2019-2020.
Conclusion
Senator Wyden’s ongoing investigation into Pfizer and other major pharmaceutical companies is a prime example of a critical examination of corporate tax practices under current U.S. tax laws. The outcome of this investigation could have significant implications for tax policy and multinational corporate taxation. For tax professionals and industry observers, staying informed about these developments will be essential as we navigate the evolving landscape of corporate taxation.
To keep updated on news, visit our Global News Page.
Don’t miss our most recent updates and articles; follow us on LinkedIn.
